Literature DB >> 30443672

Surgical consideration in Hunter syndrome: a case of hydrocephalus and a case of epidural hematoma.

Jin Li1, Xinyan Zhang2, Tao Jiang3, Chunde Li4.   

Abstract

INTRODUCTION: Hunter syndrome (HS) is a rare X-linked lysosomal storage disorder which affects multiple organ systems. Surgical intervention and general anesthesia should be used with caution because of significant airway complications. CASE REPORT: Two HS patients underwent surgery with different prognosis are presented below. In the first case, symptoms of progressive disabilities on motor function, language, intelligence, and development last for 1 year in a 6-year-old boy; magnetic resonance imaging (MRI) showed severe hydrocephalus. Third ventriculostomy was performed in this patient to relieve the hydrocephalus. Unfortunately, this patient died postoperatively due to postsurgical tracheal collapse. In the second case, an 8-year-old girl was referred to our hospital with epidural hematoma because of a falling accident. Trephination surgery was performed under local anesthesia to remove the hematoma. Three days postsurgical, the patient was discharged uneventfully.
CONCLUSION: General anesthesia in HS patients was associated with poor prognosis due to respiratory complications. Local anesthesia and less intensified treatment should be recommended.

Entities:  

Keywords:  Complications; Hunter syndrome; Surgery; Treatment

Mesh:

Year:  2018        PMID: 30443672     DOI: 10.1007/s00381-018-3998-0

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  17 in total

Review 1.  Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature.

Authors:  V I Vougioukas; A Berlis; M V Kopp; R Korinthenberg; J Spreer; V van Velthoven
Journal:  Pediatr Neurosurg       Date:  2001-07       Impact factor: 1.162

2.  Clinical outcome of cerebrospinal fluid shunting for communicating hydrocephalus in mucopolysaccharidoses I, II, and III: a retrospective analysis of 13 patients.

Authors:  Hamidreza Aliabadi; Renee Reynolds; Ciaran J Powers; Gerald Grant; Herbert Fuchs; Joanne Kurtzberg
Journal:  Neurosurgery       Date:  2010-12       Impact factor: 4.654

3.  Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).

Authors:  S A Jones; Z Almássy; M Beck; K Burt; J T Clarke; R Giugliani; C Hendriksz; T Kroepfl; L Lavery; S-P Lin; G Malm; U Ramaswami; R Tincheva; J E Wraith
Journal:  J Inherit Metab Dis       Date:  2009-07-14       Impact factor: 4.982

4.  Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).

Authors:  Torayuki Okuyama; Akemi Tanaka; Yasuyuki Suzuki; Hiroyuki Ida; Toju Tanaka; Gerald F Cox; Yoshikatsu Eto; Tadao Orii
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

Review 5.  Multidisciplinary management of Hunter syndrome.

Authors:  Joseph Muenzer; M Beck; C M Eng; M L Escolar; R Giugliani; N H Guffon; P Harmatz; W Kamin; C Kampmann; S T Koseoglu; B Link; R A Martin; D W Molter; M V Muñoz Rojas; J W Ogilvie; R Parini; U Ramaswami; M Scarpa; I V Schwartz; R E Wood; E Wraith
Journal:  Pediatrics       Date:  2009-11-09       Impact factor: 7.124

6.  Syringomyelia with obstructive hydrocephalus at the foramens of Luschka and Magendie successfully treated by endoscopic third ventriculostomy.

Authors:  Tomohiro Kawaguchi; Miki Fujimura; Teiji Tominaga
Journal:  Surg Neurol       Date:  2008-01-22

Review 7.  Diagnosis and management of respiratory involvement in Hunter syndrome.

Authors:  Wolfgang Kamin
Journal:  Acta Paediatr       Date:  2008-04       Impact factor: 2.299

Review 8.  Lysosomal disorders: from storage to cellular damage.

Authors:  Andrea Ballabio; Volkmar Gieselmann
Journal:  Biochim Biophys Acta       Date:  2008-12-08

9.  Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey.

Authors:  Nancy J Mendelsohn; Paul Harmatz; Olaf Bodamer; Barbara K Burton; Roberto Giugliani; Simon A Jones; Christina Lampe; Gunilla Malm; Robert D Steiner; Rossella Parini
Journal:  Genet Med       Date:  2010-12       Impact factor: 8.822

10.  Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients.

Authors:  Rossella Parini; Miriam Rigoldi; Lucia Tedesco; Lucia Boffi; Alessandra Brambilla; Sara Bertoletti; Agata Boncimino; Alessandra Del Longo; Paola De Lorenzo; Renato Gaini; Denise Gallone; Serena Gasperini; Carlo Giussani; Marco Grimaldi; Daniele Grioni; Pamela Meregalli; Grazia Messinesi; Francesca Nichelli; Marco Romagnoli; Pierluigi Russo; Erik Sganzerla; Grazia Valsecchi; Andrea Biondi
Journal:  Mol Genet Metab Rep       Date:  2015-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.